Showing posts with label dementia therapy. Show all posts
Showing posts with label dementia therapy. Show all posts

Monday, August 6, 2012

Those with dementia may remember when they paint



Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Caring.com

Stories of how people with Alzheimer's spark to creative activities involving art, music, and literature are fascinating to hear – and even more so to witness. Better yet, arts activities make life less stressful for dementia caregivers, which is why I can't revisit this topic enough.
  • When my son played guitar for a group of residents in the dementia wing of a nursing home where his grandpa lived for rehab, one woman prone to violence and wandering restlessly planted herself in front of him to happily dance and dance.
  • A friend recently told me her mother, who has advanced Alzheimer's, mostly sits locked into her own silent world, until her daughter plays church hymns on the piano. Then Mom sings every word, clear as a bell.
  • Alzheimer's disease turned actress Rita Hayworth anxious, aggressive, and confused – except when she was painting flowers, a hobby she took up late, and with gusto.
  • A former teacher, new to a long-term dementia care facility, is restless and agitated until he's made the leader of a book group. Passing out books and reading aloud with other residents from large-type books becomes a daily focus and motivation.

Obviously nobody paints or plays music 24/7. And it would be hard for a dementia caregiver to organize artsy activities all day long. But don't be too quick to think it's not for you. You don't have to be a sophisticated arts therapist or spend a lot of energy to reap the benefits:
  1. Arts participation gives someone with dementia a sense of accomplishment and pleasure; the resulting positive emotions reverberate throughout your day.
  2. Finding the right "spark" gives you a go-to activity to help change mood in a pinch, when your loved one is upset or bored.
  3. Going out to, say, a concert or a museum in early- to mid-stage disease gets you both out of the house.
"Alzheimer's doesn't take away memory; your memories are all in there. The part of the brain that's damaged is the part that gives you access to memory. It's as if you put the memories in the glove compartment and you lost the key – and the art unlocked it," says John Zeisel, a sociologist who founded Artz for Alzheimer's, a very cool organization that sets up guided museum tours for people with Alzheimer's, among other programs. Zeisel is also the author of last year's I'm Still Here: A Breakthrough Approach to Understanding Someone Living With Alzheimer's.
Some ideas to get you started:
  • Don't assume the arts have no effect if your loved one was never "artsy." Music and painting reach many people with dementia, even the unlikeliest.
  • Experiment. Some people take to dance, others like to pluck a zither or work in fingerpaint. Rent musicals to watch. Visit a museum every Friday afternoon – it can be the same place, looking at the same art, every week; it's the routine and in-the-moment experience that helps.
  • Keep it simple. My Dad, a lifelong photographer, could no longer operate even the simplest camera, but he never lost his enjoyment of polka music. Paint-by-numbers? Maybe not. Watercolor? Who knew your mom was an Impressionist?
  • It's art therapy, not art class. As you look at paintings or art books, resist the urge to quiz about artists or famous works. Just talk about the colors, shapes, and emotions: "Do you like it? How about this one?"

Tuesday, July 31, 2012

Doctors criticize IViG therapy for dementis


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

ABC News

Doctors Criticize IViG Study Results

Still, treatment is not advised for patients who have had a major stroke or heart attack, because it can increase the risk of vascular events.
IVIG may not just be a therapy that treats symptoms, according to Dr. Richard Caselli, a neurologist at the Mayo Clinic. The drug seems to block the "destructive process" of inflammation mechanisms in the brain.
"Its strength and therefore importance is that it seems to show a stabilizing effect over a sustained period of time," he said. "Its weakness as the authors state is the small number of patients as well as its unblinded open label format."
But Dr. Normal Foster at the Center for Alzheimer's Care, Imaging and Research at the University of Utah, said the selective reporting of the study's results are "suspicious."
"Not everyone who received treatment was included in the analysis," he said. "The results are intriguing, and I can see why they might want to share them, but they can't be relied upon."
Dr. James E. Galvin, director of the the Pearl Barlow Center for Memory Evaluation and Treatment at New York University's Langone Medical Center, said there may be "technical and logistical limitations" in how many patients might obtain the drug.
Natural Alzheimer's Remedies?Watch Video
Getting Alzheimer's Candidate to Doctor? Watch Video
Welcome to OnCall+ Alzheimer'sWatch Video
But Dr. Sam Gandy, director of Mount Sinai Center for Cognitive Health, said the study, though small, is "still good news, indeed."
He, like other experts, said more studies were needed to prove the drug's promise.
Marder showed no symptoms of the disease in his speech, memory or mood when interviewed by ABCNews.com. He said he first began noticing he was having trouble with his memory a decade ago.
"I thought it was all part of aging," he said.
After a series of tests with a neurologist that were inconclusive, he was preventively put on the drug Aricept. But within a matter of months, an official diagnosis of Alzheimer's disease was made.
"I was devastated," he said. "It blows you away."
As his confusion and forgetfulness worsened, Marder was put on Namenda, as well as Aricept, both of which he has continued for nine years.
Every six months Relkin puts Marder through a series of cognitive tests and so far, the decline has been minimal.
But now, the Marders worry that they may not get the drug if it does not get FDA approval when phase III clinical trials end next year.
And it's expensive – estimated to cost a patient $2,000 to $5,000 every two weeks, including the drug, equipment and a nurse to administer it.
Relkin has told the Marders there were other drugs, but Marder said, "I just want them to keep going."
Marder continues to play tennis and can ride his bike up the 11-mile stretch from Battery Park to the George Washington Bridge -- and back.
"He still has memory issues, no question," said his wife. He tends to repeat himself, but the drug has kept him stable. "There's no doubt he has Alzheimer's, but we would have expected him to progress downward by now."
Luckily, Marder has the self-awareness to know what the drug has done for him.
"It's heaven," he said. "I don't know where I could have been without it.

Sunday, July 29, 2012

IViG therapy shows some success for treating dementia


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

ABC News


Jason Marder watched the inevitable decline of his younger brother, who died of Alzheimer's disease at the age of 50. Then, just after his 60th birthday, he too, began to exhibit subtle, early symptoms -- forgetfulness and difficulty focusing on conversations.
At his birthday party, "I noticed he had a hard time keeping track of the presents," said he wife, Karin Marder. "He would forget small things -- like saying he went to the movies when he didn't."
The memory loss progressed, and in 2004, Marder got the dreaded diagnosis: Alzheimer's, a disease that affects 5.1 million Americans.
"It was devastating," said his wife, who works in business apparel. "I thought our lives were going to end."
But today, eight years after his diagnosis, Marder isn't any worse off. He has shown no further memory loss and has remained stable.
The Marders credit intravenous immunoglobulin, or IViG, therapy and a clinical trial that is swirling in controversy this week after an announcement of study results by the Alzheimer's Association International Conference 2012 in Vancouver.
Some doctors hailed the therapy as "exciting," something that could potentially stabilize the disease, while others said the research is inconclusive and the study -- with only 16 subjects -- was too small.
Nonetheless, today Marder, now retired from working in apparel, continues his independent lifestyle, playing tennis and biking in his native New York City.
"Things are going really nicely. I can't complain," said Marder, now 70. "I don't feel any going backwards."
Natural Alzheimer's Remedies?Watch Video
Getting Alzheimer's Candidate to Doctor? Watch Video
Welcome to OnCall+ Alzheimer'sWatch Video
"This drug saved his life," said Karin Marder. "He's independent. He gets on the subways, bikes up and down the Hudson River, gets to go out with friends. He goes to the senior center twice a week. He does creative writing."
For the past five years, Marder has been part of a clinical trial with Dr. Norman R. Relkin, director of the Memory Disorders Program at New York-Presbyterian/Weill Cornell Medical Center.
Relkin presented data that found,overall, that 11 study participants who received the immunotherapy Gammagard (IViG) for three full years showed improvements in cognition, memory, daily functioning and mood.
"We are seeing encouraging results," Relkin told ABCNews.com. And despite negative publicity, "I don't want people to give up hope for symptomatic treatment of the disease".
Intravenous Immunoglobulin is a mixture that contains molecules pooled from plasma, a component of human blood. It is used to treat various autoimmune, infectious and idiopathic diseases, and its supply is therefore limited.
IViG works by using the body's natural defense or immune system and anti-amyloid antibodies. A protein called beta amyloid accumulates in the brain of those who have Alzheimer's.
"We don't know exactly what it targets, but we do know it contains all antibodies that the body produces," said Relkin. "It alters the function of the immune system and decreases inflammation in the brain".
He said that his research team found the rate of brain shrinkage had slowed and the study had "exceeded criteria" to go forward with a phase III trial.
"Typically, untreated Alzheimer's disease shows cognitive decline in three to six months," said Relkin. "Those treated with typical AD drugs show decline in six to nine months. Four out of four patients in the [phase IIB] extension trial were unchanged over a three-year period."
As for Marder, he still has some memory problems, but he can dress himself, cook, clean and walk around the neighborhood.
"I can be away from him for one to two nights," said his wife, Karin.
Every two weeks, a nurse comes to Marder's home and sets up the infusion, which takes about four hours.
"I am happy to spend the time," he said. "Then I walk out of my house and go bike riding."
Besides a minor rash that crops up three to five days after getting the drug, Marder has had no ill side effects with the treatment. "He hasn't even had a cold in five years," said Marder's wife.

Friday, May 18, 2012

Researchers move closer to delaying dementia


Here is a great dementia resource for caregivers and healthcare professionals,


You will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow Alzheimers1 on twitter

UQ News

Scientists at UQ's Queensland Brain Institute are one step closer to developing new therapies for treating dementia.



QBI's Dr Jana Vukovic said the work was aimed at understanding the molecular mechanism that may impair learning and memory in the aging population.


“Aging slows the production of new nerve cells, reducing the brain's ability to form new memories,” said Dr Vokovic, who performed the work in the laboratory of Professor Perry Bartlett, the Director of QBI at The University of Queensland.


"But our research shows for the first time that the brain cells usually responsible for mediating immunity, microglia, have an inhibitory effect on memory during aging.


“Furthermore, they have shown that a molecule produced by nerve cells, fractalkine, can reverse this process and stimulate stem cells to produce new neurons.”


The discovery, published in The Journal of Neuroscience today, came after QBI scientists observed that the increased production of new neurons in mice that were actively running was due to the release of fractalkine in the hippocampus – the brain structure responsible for specific types of learning and memory.

Professor Bartlett said it had been known for some time that exercise increased the production of new nerve cells in the hippocampus in young and even aged mice.

“But this study found that it is fractalkine that appears to be specifically mediating this effect by making the microglia produce factors that activate the stem cells that produce new nerve cells,” he said.

“Once the cells are activated they divide and produce new cells, which underpin the animal's ability to learn and form memories.



"This means that fractalkine may form the basis for the development of future therapies.

“The discovery is especially exciting because we have found that older animals suffering cognitive decline showed significantly lower levels of fractalkine.

“We are seeking ways of increasing fractalkine levels in patients with cognitive decline, and hoping this may be a new frontline therapy in treating dementia.”


Dr Vukovic said that until relatively recently, it was thought the adult brain was incapable of generating new neurons.

“But work from Professor Bartlett's laboratory over the past 20 years has demonstrated that the brains of adult animals, including humans, retain the ability to make new nerve cells,” she said.


“The challenge is to find out how to stimulate this production in the aged animal and human where production has slowed.”

The latest work was a significant step toward achieving this goal, she said.


The article published today is titled Microglia modulate hippocampal neural precursor activity in response to exercise and aging. Its authors are Jana Vukovic, Michael J. Colditz, Daniel G. Blackmore, Marc J. Ruitenberg, Perry F. Bartlett




Saturday, April 14, 2012

Dementia therapy-:patch or pill

cholinHere is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Family Practice News

If you’re stumped about which cholinesterase inhibitor to prescribe for your patients with newly diagnosed Alzheimer’s disease, rest assured that the clinical effects are similar with all such agents.

"There is no substantive scientific evidence that says one of the cholinesterase inhibitors is better than another, so get comfortable with one or two of them," Dr. Jeffrey L. Cummings advised during a psychopharmacology conference sponsored by the Nevada Psychiatric Association. "The effect is demonstrable late in the disease, so if you take patients with Mini-Mental State Exam scores of less than 10, you still get the same response that you do in somebody whose Mini-Mental State Exam score is 20. There’s no proven effect on the underlying disease state."

Clinical evidence from nearly 20 years of cholinesterase inhibitor use suggests that 25% of patients who take them will experience modest cognitive improvements, defined as a 2-4 point increase on the Alzheimer’s Disease Assessment Scale-cognitive subscale or a 1-2 point increase on the Mini-Mental State Exam. This "makes it very difficult to see a response if it’s not on the upper end of that [response]," Dr. Cummings said. "But about 80% of patients on cholinesterase inhibitors have a delay in decline of 6-9 months. That’s worthwhile, because patients are usually only on therapy for about 5 or 6 years over the course of their disease. So if you can delay almost 20% of that, that’s fantastic."

Dr. Cummings, director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health, lets convenience drive the choice of which cholinesterase inhibitor to prescribe. "I sit with the patient and the caregiver and I ask: ‘Do you want a pill or a transdermal patch?’ If they say, ‘I want a pill,’ I give them donepezil. If they say, ‘I want a patch,’ I give them the rivastigmine transdermal patch," he said.

"I’m trying to respond to the perceived convenience of the caregiver. That’s the question I pose, and those are the two drugs I use."

He went on to note that donepezil "is more likely to give you diarrhea than rivastigmine is, and the rivastigmine patch will give you a rash in 5-10% of patients. Bradycardia is a contraindication for all cholinesterase inhibitors."

Donepezil is available in 5-mg, 10-mg, and 23-mg formulations. The 23-mg form is approved only for patients with moderate to severe disease. "There is more diarrhea with the 23-mg dose; maybe 15% of patients will get diarrhea with that higher dose," he said. "To ameliorate this, for 1 month I have patients go from 10 mg to 15 mg before jumping to the 23-mg dose. I think that helps rather than going directly from 10 mg to 23 mg."

Rivastigmine is approved for mild to moderate Alzheimer’s and for patients with mild to moderate Parkinson’s disease dementia. It’s available in 1.5-mg, 3-mg, 4.5-mg, and 6-mg capsules, or as a 4.6-mg or 9.5-mg transdermal patch.

Galantamine is another cholinesterase inhibitor approved for patients with mild to moderate Alzheimer’s disease, and it has dosing options of 6 mg, 8 mg, or 12 mg b.i.d. Extended formulations are available in 12-mg and 24-mg doses.
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info